title: [Influence of preoperative transcatheter arterial chemoembolism on immunity after hepatectomy in patients with liver cancer].
abstract: OBJECTIVE
  Transcatheter arterial chemoembolism (TACE) is one of important therapeutic method for hapatocarcinoma. Post-operative TACE could reduce recurrent rate definitely. However, there were much debate about the function and effect of preoperative TACE. This study was conducted to evaluate the effect of preoperative TACE on immunity of the patients with recurrent hepatocarcinoma who performed combined treatment.
  
  
  METHODS
  The patients with primary hepatocarcinoma who performed operative TACE were collected. The dynamic changes of cellular immunity and humoral immunity in pre-intervention, pre-operation, combined treatment after recurrence periods were determined by flow cytometry and ELISA, and were compared with the data of the recurrent patients after simple operation.
  
  
  RESULTS
  In TACE group: CD3, CD4, CD56 decreased slightly; serum IgM increased slightly, with no significant difference compared to pre-intervention (P < 0.05); At the time of combined treatment after recurrence, CD8 increased and CD4/CD8 decreased (0.8 +/- 0.3%), the immune suppression was slight. In sample operation group, CD3, CD4, CD56 were 49.0 +/- 9.1%, 19.0 +/- 4.8%, 18.6 +/- 9.9%; the immune suppression was severe. The operation significantly decreased the patients' CD3, CD4, and CD19. The pathologic results showed that the tumor capsule, intrahepatic daughter foci, tumor thrombus, and the radical degree in preoperative group were much better than those in simple operation group.
  
  
  CONCLUSIONS
  The preoperative TACE do not obviously influence the immunity; furthermore, it can relieve the immune depression after operation and is a remedy of the surgical treatment. It is important to grasp the indication of preoperative TACE.
authors.affiliation: Department of Hepatobiliary Surgery, Cancer Center, Sun-Yat-sen University, Guangzhou 510060, P. R. China.
authors.forename: Xiao-kang
authors.initials: XK
authors.lastname: Su
authors.forename: Chang-qing
authors.initials: CQ
authors.lastname: Zhang
authors.forename: Rong-ping
authors.initials: RP
authors.lastname: Guo
authors.forename: Min-shan
authors.initials: MS
authors.lastname: Chen
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Ling
authors.forename: Ming
authors.initials: M
authors.lastname: Shi
authors.forename: Yun
authors.initials: Y
authors.lastname: Zheng
authors.forename: Jin-qing
authors.initials: JQ
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D018941:Antigens, CD19 / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology; D019002:CD56 Antigen / Q000276:immunology; D016827:CD8 Antigens / Q000276:immunology; D003176:Complement C3 / Q000276:immunology; D003181:Complement C4 / Q000276:immunology; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D006498:Hepatectomy; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D008113:Liver Neoplasms / Q000276:immunology* / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D018941:Antigens, CD19; D017252:CD3 Complex; D015704:CD4 Antigens; D019002:CD56 Antigen; D016827:CD8 Antigens; D003176:Complement C3; D003181:Complement C4; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D015375:Receptors, Interleukin-2